Keeps Biopharma Inc. (KOSDAQ:256940)
South Korea
· Delayed Price · Currency is KRW 15,980
-130 (-0.81%)
At close: May 30, 2025, 3:30 PM KST
Keeps Biopharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Operating Revenue | 127,583 | 92,133 | 14,617 | 4,261 | 15,217 | Upgrade
|
| Other Revenue | -0 | - | - | 0 | - | Upgrade
|
| Revenue | 127,583 | 92,133 | 14,617 | 4,261 | 15,217 | Upgrade
|
| Revenue Growth (YoY) | 38.48% | 530.30% | 243.09% | -72.00% | 7.23% | Upgrade
|
| Cost of Revenue | 110,343 | 79,336 | 13,574 | 5,050 | 11,269 | Upgrade
|
| Gross Profit | 17,240 | 12,798 | 1,044 | -788.97 | 3,947 | Upgrade
|
| Selling, General & Admin | 9,921 | 7,302 | 6,076 | 5,475 | 3,032 | Upgrade
|
| Research & Development | 801.38 | 1,450 | 2,164 | 2,810 | 829.9 | Upgrade
|
| Other Operating Expenses | 226.14 | 441.16 | 41.37 | 46.25 | 68.48 | Upgrade
|
| Operating Expenses | 11,015 | 9,738 | 9,958 | 11,518 | 4,334 | Upgrade
|
| Operating Income | 6,225 | 3,060 | -8,915 | -12,307 | -386.94 | Upgrade
|
| Interest Expense | -3,731 | -2,030 | -934.7 | -1,690 | -1,665 | Upgrade
|
| Interest & Investment Income | 733.24 | 1,012 | 1,075 | 431.37 | 303.49 | Upgrade
|
| Earnings From Equity Investments | -1,609 | 4,930 | -3,998 | -3,081 | -2,184 | Upgrade
|
| Currency Exchange Gain (Loss) | 2,307 | 531.9 | 1,480 | 1,869 | -1,135 | Upgrade
|
| Other Non Operating Income (Expenses) | -1,429 | -3,132 | -3,237 | 10.54 | 3.76 | Upgrade
|
| EBT Excluding Unusual Items | 2,496 | 4,372 | -14,530 | -14,767 | -5,064 | Upgrade
|
| Impairment of Goodwill | -81.54 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 847.49 | 1,033 | -203.11 | -2,519 | 2,871 | Upgrade
|
| Gain (Loss) on Sale of Assets | 24.15 | -33.36 | 2.44 | -19.15 | -82.9 | Upgrade
|
| Other Unusual Items | 83.7 | - | 853.14 | - | - | Upgrade
|
| Pretax Income | 3,370 | 5,372 | -13,877 | -17,305 | -2,276 | Upgrade
|
| Income Tax Expense | 1,758 | 1,909 | -1,837 | -1,074 | 271.45 | Upgrade
|
| Earnings From Continuing Operations | 1,612 | 3,463 | -12,040 | -16,231 | -2,547 | Upgrade
|
| Minority Interest in Earnings | -498.28 | 467.19 | 665.13 | 913.17 | 140.9 | Upgrade
|
| Net Income | 1,113 | 3,930 | -11,375 | -15,317 | -2,406 | Upgrade
|
| Net Income to Common | 1,113 | 3,930 | -11,375 | -15,317 | -2,406 | Upgrade
|
| Net Income Growth | -71.67% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 19 | 19 | 19 | 17 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 19 | 19 | 19 | 17 | 15 | Upgrade
|
| Shares Change (YoY) | 0.38% | 0.40% | 8.22% | 18.22% | 14.07% | Upgrade
|
| EPS (Basic) | 59.39 | 209.62 | -607.03 | -884.60 | -164.28 | Upgrade
|
| EPS (Diluted) | 59.00 | 209.00 | -607.03 | -884.60 | -164.28 | Upgrade
|
| EPS Growth | -71.77% | - | - | - | - | Upgrade
|
| Free Cash Flow | -1,787 | -1,048 | -962.12 | -8,471 | -2,780 | Upgrade
|
| Free Cash Flow Per Share | -94.64 | -55.71 | -51.34 | -489.19 | -189.82 | Upgrade
|
| Gross Margin | 13.51% | 13.89% | 7.14% | -18.52% | 25.94% | Upgrade
|
| Operating Margin | 4.88% | 3.32% | -60.99% | -288.86% | -2.54% | Upgrade
|
| Profit Margin | 0.87% | 4.27% | -77.82% | -359.52% | -15.81% | Upgrade
|
| Free Cash Flow Margin | -1.40% | -1.14% | -6.58% | -198.82% | -18.27% | Upgrade
|
| EBITDA | 8,807 | 4,502 | -7,921 | -11,495 | 217.34 | Upgrade
|
| EBITDA Margin | 6.90% | 4.89% | -54.19% | -269.79% | 1.43% | Upgrade
|
| D&A For EBITDA | 2,582 | 1,442 | 993.33 | 812.4 | 604.28 | Upgrade
|
| EBIT | 6,225 | 3,060 | -8,915 | -12,307 | -386.94 | Upgrade
|
| EBIT Margin | 4.88% | 3.32% | -60.99% | -288.86% | -2.54% | Upgrade
|
| Effective Tax Rate | 52.17% | 35.53% | - | - | - | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.